Evidence mapPaperPMID 41975517Full record

ArticleMolecular neurodegeneration2026

Regional diffusion imaging measures to disentangle SVD-related hypertensive arteriopathy versus cerebral amyloid angiopathy.

Sheelakumari Raghavan, Scott A Przybelski, Robel K Gebre, Audrey Low, Mingzhao Hu, Robert I Reid, B Gwen Windham, Heather J Wiste, Angela J Fought, Michael G Kamykowski and 8 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sheelakumari RaghavanDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Raghavan.Sheela@mayo.edu.
Scott A PrzybelskiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Robel K GebreDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Audrey LowDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Mingzhao HuDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Robert I ReidDepartment of Information Technology, Mayo Clinic, Rochester, MN, 55905, USA.
B Gwen WindhamDepartment of Medicine, The MIND Center, University of Mississippi Medical Center, Jackson, FL, 39216, USA.
Heather J WisteDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Angela J FoughtDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Michael G KamykowskiDepartment of Information Technology, Mayo Clinic, Rochester, MN, 55905, USA.
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Melissa E MurrayDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, 32224, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Clifford R Jr JackDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, 55905, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Vemuri.prashanthi@mayo.edu.
Alzheimer’s Disease Neuroimaging Initiative

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI Jonathan Graff-Radford, CLIFFORD R. JACK · 1986 to 2023
$10.8M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · MAYO CLINIC ROCHESTER · 2025 to 2025
$770k
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · MAYO CLINIC ROCHESTER · 2025 to 2025
$764k
NIA NIH HHS R01 AG056366NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

backgroundDetecting and distinguishing early changes due to the two key subtypes of cerebral small vessel disease (SVD), hypertensive arteriopathy (HA) and cerebral amyloid angiopathy (CAA), has significant clinical implications. Our goal was to develop and validate dMRI signatures associated with HA-SVD and CAA-SVD proxies and assess their clinical utility using Alzheimer’s disease and SVD biomarkers, pathology, and cognition.

methodsTwo independent cohorts with baseline dMRI scans, T2* gradient-echo MRI, and vascular risk measures were analyzed: Mayo Clinic Study of Aging (MCSA, N = 1080) and Alzheimer’s Disease Neuroimaging Initiative (ADNI, N = 549). In MCSA, regional dMRI measures associated with proxies of HA-SVD (hypertension) and CAA-SVD (lobar cerebral microbleeds) were identified using logistic regression models. The top regional features were then used to compute composite dMRI indices for HA-SVD and CAA-SVD. These dMRI indices were validated in ADNI and in an independent pathology sample of MCSA (N = 147). In MCSA, we also computed standard global SVD indices from diffusion and FLAIR MRI and compared them with dMRI indices to reflect SVD subtypes. Next, we evaluated the association of these indices with cognitive performance (global, attention, and memory) using regression models, after adjusting demographics, white matter hyperintensities (WMH) and amyloid.

resultsHypertension was associated with reduced microstructural integrity predominantly in fronto-parieto-projection pathways, whereas lobar microbleeds were associated with occipito-parietal damage. These differential tract association patterns with HA-SVD and CAA-SVD proxies were less pronounced in ADNI. In the community-dwelling MCSA cohort with higher prevalence of vascular disease, dMRI indices provided more differentiated associations with both proxies of SVD than global SVD indices, underscoring added value for etiology-specific identification. As expected, CAA-SVD indices were more strongly associated with occipital WMH and amyloid burden and were linked to CAA pathology scores. CAA-SVD indices also had greater association with memory performance, independent of amyloid and WMH. Conversely, HA-SVD indices were robustly associated with post-mortem Kalaria scales and attention scores.

conclusionsUsing three datasets, (population-based sample, independent cohort, pathology sample), we found that regional dMRI signatures can capture distinct SVD processes of HA and CAA. These dMRI signatures offer potential for early differential identification of SVD subtypes and can aid in guiding clinical decision making and prevention.

Indexed as

Cerebral Amyloid AngiopathyCerebral Small Vessel DiseasesDiffusion Magnetic Resonance ImagingHypertensionAgedAged, 80 and overAlzheimer DiseaseBrainCohort StudiesFemaleHumansMaleCerebral amyloid angiopathyCognitionDiffusion MRIHypertensive arteriopathyPathologySmall vessel disease

Identifiers

PMID41975517
PMCPMC13185335

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.